A high-throughput screen to identify novel small molecule inhibitors of the Werner Syndrome Helicase-Nuclease (WRN)
Fig 9
Effects of WRN helicase inhibitors on cancer cell proliferation.
(A) Cell proliferation of HeLa 1.2.11 cells treated with 50 μM NCGC00029283-03, NCGC00063279-03, NCGC00357377-01 and NSC 617145 (positive control) or vehicle (DMSO) on Day 0 and Day 3 as measured using the WST-1 cell proliferation reagent. (B) Cell proliferation of U2-OS cells treated with increasing amounts of NCGC00029283-03 (0–100 μM) from Day 0 through Day 3. (C) Cell proliferation of U2-OS cells treated with increasing amounts of NCGC00063279-03 (0–100 μM) from Day 0 through Day 3. (D) Cell proliferation of U2-OS cells treated with 100 μM NCGC00357377-01 from Day 0 through Day 3.